Search
Mostrar filtros
Add filters:
Use filters to refine the search results.
Results 1-10 of 15 (Search time: 0.011 seconds).
Issue Date | Title | Author(s) |
---|---|---|
2014 | Paclitaxel Delivered With Nanoparticles Inhibits Neointimal Formation and Local Inflammation in Experimental Chronic Allograft Vasculopathy | PEPINELI, R.; SANTANA, A.; TIEME, A.; DEUS, D.; MARANHAO, R.; NORONHA, I. |
2014 | Was the PON1-55MM Polymorphism Associated to Higher Disease Severity in Common Variable Deficiency Patients? | SINI, B. C.; BYDLOWSKI, S. P.; LEVY, Debora; MASELLI, Luciana M. F.; COHON, Andrea; KOKRON, Cristina M.; OLIVEIRA, Ana Karolina Barreto; KALIL, Jorge; BARROS, Myrthes Toledo |
2014 | Paclitaxel Delivered With Nanoparticles Inhibits Neointimal Formation and Local Inflammation in Experimental Chronic Allograft Vasculopathy. | PEPINELI, R.; SANTANA, A.; TIEME, A.; DEUS, D.; MARANHAO, R.; NORONHA, I. |
2014 | IN BOTH GENDERS, HIGH RATE UNESTERIFIED CHOLESTEROL TRANSFER TO HDL IN THE PLASMA CAN BE PROTECTIVE AGAINST CORONARY ARTERY DISEASE | SPRANDEL, M. C. O.; HUEB, W. A.; SEGRE, A. C.; LAVERDY, O. G.; LEITE-JUNIOR, A. C.; FREITAS, F. R.; KALIL-FILHO, R.; MARANHAO, R. C. |
2014 | Orbitofrontal Thickness as a Measure for Treatment Response Classification in Obsessive-Compulsive Disorder | HOEXTER, Marcelo; DINIZ, Juliana; LOPES, Antonio; BATISTUZZO, Marcelo; SHAVITT, Roseli; DOUGHERTY, Darin; DURAN, Fabio; BRESSAN, Rodrigo; BUSATTO, Geraldo; MIGUEL, Euripedes; SATO, Joao |
2014 | Clinical Prognostic Models in Diffuse Large B-Cell Lymphoma Patients Are Still Essential in the Rituximab Era | LAGE, Luis Alberto de Padua Covas; COSTA, Renata Oliveira; HALLACK NETO, Abrahao Elias; SIQUEIRA, Sheila; SANTUCCI, Rodrigo; PAULA, Henrique Moura de; PEREIRA, Juliana |
2014 | CD4+Lymphocytes in Asymptomatic HTLV-1 Carriers Present Cell Cycle Arrest in G0/G1-Phase | FERREIRA, Mari Cleia Martins Rodrigues; FOLTRAN, Renata Kikuchi; SANTUCCI, Rodrigo; LAGE, Luis Alberto de Padua Covas; LEVY, Debora; PEREIRA, Juliana |
2014 | Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study | ROBAK, Tadeusz; HUANG, Huiqiang; JIN, Jie; ZHU, Jun; LIU, Ting; SAMOILOVA, Olga S.; PYLYPENKO, Halyna; VERHOEF, Gregor; SIRITANARATKUL, Noppadol; OSMANOV, Evgenii A.; ALEXEEVA, Julia; PEREIRA, Juliana; MAYER, Jiri; HONG, Xiaonan; MAEDA, Yoshiharu; PEI, Lixia; ROONEY, Brendan; VELDE, Helgi van de; CAVALLI, Franco |
2014 | 18 F-FDG PET Interim and Determination of Cellular Origin By Immunohistochemistry Identify a Group of Very Good Prognosis in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era | LAGE, Luis Alberto de Padua Covas; COSTA, Renata Oliveira; HALLACK NETO, Abrahaeo Elias; SIQUEIRA, Sheila; SANTUCCI, Rodrigo; PAULA, Henrique Moura de; PEREIRA, Juliana |
2014 | Comparison Between R-CHOP Vs R-CHOP Plus Etoposide in Untreated Patients with Primary Mediastinal B-Cell Lymphoma: Preliminary Findings | MACIEL, Felipe Vieira Rodrigues; SZOR, Roberta Shcolnik; LEVY, Debora; SANTUCCI, Rodrigo; PEREIRA, Juliana |